Top

Published in:

Open Access 01-12-2018 | Original Article

Mitochondrial alterations accompanied by oxidative stress conditions in skin fibroblasts of Huntington’s disease patients

Authors: Paulina Jędrak, Paweł Mozolewski, Grzegorz Węgrzyn, Mariusz R. Więckowski

Published in: Metabolic Brain Disease | Issue 6/2018

Abstract

Huntington disease (HD) is an autosomal dominant neurodegenerative disorder manifesting as progressive impairment of motor function and different neuropsychiatric symptoms caused by an expansion of CAG repeats in huntingtin gene (HTT). Mitochondrial dysfunction and bioenergetic defects can contribute to the course of the disease, however, the molecular mechanism underlying this process is still largely unknown. In this study, we aimed to determine several mitochondrial parameters in HD fibroblasts and assess their relevance to the disease progression as well as to value mitochondrial pathology in peripheral cells as disease potential biomarker. We showed that HD fibroblasts demonstrate significantly lower growth rate compared to control fibroblasts despite the lack of cell cycle perturbations. In order to investigate mitochondrial contribution to cell growth differences between HD and healthy cells, we provided insight into various mitochondrial parameters. Conducted experiments have revealed a significant reduction of the ATP level in HD fibroblasts accompanied by a decrease in mitochondrial metabolic activity in relation to the cells from healthy donors. Importantly, there were no differences in the mitochondrial membrane potential (mtΔΨ) and OXPHOS complexes’ levels. Slightly increased level of mitochondrial superoxide (mt. O₂^•-), but not cytosolic reactive oxygen species (cyt. ROS), has been demonstrated. We have also observed significantly elevated levels of some antioxidant enzymes (SOD2 and GR) which may serve as an indicator of antioxidant defense system in HD patients. Thus, we suggest that mitochondrial alterations in skin fibroblasts of Huntington’s disease patients might be helpful in searching for novel disease biomarkers.

Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, Sanchez-Pernaute R, de Yébenez JG, Boesiger P, Weindl A, Maguire RP (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington’s disease. Brain 119:2085–2095CrossRef

Arenas J, Campos Y, Ribacoba R, Martín MA, Rubio JC, Ablanedo P, Cabello A (1998) Complex I defect in muscle from patients with Huntington’s disease. Ann Neurol 43:397–400. https://doi.org/10.1002/ana.410430321 CrossRefPubMed

Bates G, Harper PJL (2002) Huntington’s disease, 3rd edn. Oxford University press, Oxford

Beglinger LJ, O’Rourke JJF, Wang C et al (2010) Earliest functional declines in Huntington disease. Psychiatry Res 178:414–418. https://doi.org/10.1016/J.PSYCHRES.2010.04.030 CrossRefPubMedPubMedCentral

Browne SE (2008) Mitochondria and Huntington’s disease pathogenesis. Ann N Y Acad Sci 1147:358–382. https://doi.org/10.1196/annals.1427.018 CrossRefPubMed

Browne SE, Bowling AC, MacGarvey U et al (1997) Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann Neurol 41:646–653. https://doi.org/10.1002/ana.410410514 CrossRefPubMed

Busner J, Targum SD (2007) The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 4:28–37

Chabi B, Mousson De Camaret B, Duborjal H et al (2003) Quantification of mitochondrial DNA deletion, depletion, and overreplication: application to diagnosis. Clin Chem 49:1309–1317. https://doi.org/10.1373/49.8.1309 CrossRefPubMed

Chen X, Guo C, Kong J (2012) Oxidative stress in neurodegenerative diseases. Neural Regen Res 7:376–385. https://doi.org/10.3969/j.issn.1673-5374.2012.05.009 CrossRefPubMedPubMedCentral

Chiang M-C, Chern Y, Huang R-N (2012) PPARgamma rescue of the mitochondrial dysfunction in Huntington’s disease. Neurobiol Dis 45:322–328. https://doi.org/10.1016/j.nbd.2011.08.016 CrossRefPubMed

del Hoyo P, García-Redondo A, de Bustos F, Molina JA, Sayed Y, Alonso-Navarro H, Caballero L, Arenas J, Jiménez-Jiménez FJ (2006) Oxidative stress in skin fibroblasts cultures of patients with Huntington’s disease. Neurochem Res 31:1103–1109. https://doi.org/10.1007/s11064-006-9110-2 CrossRefPubMed

Djoussé L, Knowlton B, Cupples LA et al (2002) Weight loss in early stage of Huntington’s disease. Neurology 59:1325–1330CrossRef

Filosto M, Scarpelli M, Cotelli MS, Vielmi V, Todeschini A, Gregorelli V, Tonin P, Tomelleri G, Padovani A (2011) The role of mitochondria in neurodegenerative diseases. J Neurol 258:1763–1774. https://doi.org/10.1007/s00415-011-6104-z CrossRefPubMed

Firdaus WJJ, Wyttenbach A, Giuliano P, Kretz-Remy C, Currie RW, Arrigo AP (2006) Huntingtin inclusion bodies are iron-dependent centers of oxidative events. FEBS J 273:5428–5441. https://doi.org/10.1111/j.1742-4658.2006.05537.x CrossRefPubMed

Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, Wheeler VC, Persichetti F, MacDonald M (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington’s disease knock-in mice. Hum Mol Genet 12:497–508CrossRef

Gu M, Gash M, Mann VM (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39:385–389. https://doi.org/10.1002/ana.410390317 CrossRefPubMed

Guidetti P, Charles V, Chen E-Y, Reddy PH, Kordower JH, Whetsell WO Jr, Schwarcz R, Tagle DA (2001) Early degenerative changes in transgenic mice expressing mutant Huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol 169:340–350. https://doi.org/10.1006/exnr.2000.7626 CrossRefPubMed

Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, Watkins PC, Ottina K, Wallace MR, Sakaguchi AY, Young AB, Shoulson I, Bonilla E, Martin JB (1983) A polymorphic DNA marker genetically linked to Huntington’s disease. Nature 306:234–238CrossRef

Gutekunst CA, Li SH, Yi H, Ferrante RJ, Li XJ, Hersch SM (1998) The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): comparison with huntingtin in rat and human. J Neurosci 18:7674–7686CrossRef

Hands S, Sajjad MU, Newton MJ, Wyttenbach A (2011) In vitro and in vivo aggregation of a fragment of huntingtin protein directly causes free radical production. J Biol Chem 286:44512–44520. https://doi.org/10.1074/jbc.M111.307587 CrossRefPubMedPubMedCentral

Harjes P, Wanker EE, Bates G et al (2003) The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem Sci 28:425–433. https://doi.org/10.1016/S0968-0004(03)00168-3 CrossRefPubMed

Huntington Study Group (1996) Unified Huntington’s disease rating scale: reliability and consistency. Mov Disord 11:136–142CrossRef

Jędrak P, Krygier M, Tońska K, Drozd M, Kaliszewska M, Bartnik E, Sołtan W, Sitek EJ, Stanisławska-Sachadyn A, Limon J, Sławek J, Węgrzyn G, Barańska S (2017) Mitochondrial DNA levels in Huntington disease leukocytes and dermal fibroblasts. Metab Brain Dis 32:1237–1247. https://doi.org/10.1007/s11011-017-0026-0 CrossRefPubMedPubMedCentral

Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR (1993) Evidence for impairment of energy metabolism in vivo in Huntington’s disease using localized 1H NMR spectroscopy. Neurology 43:2689–2695CrossRef

Johri A, Beal MF (2012) Antioxidants in Huntington’s disease. Biochim Biophys Acta 1822:664–674. https://doi.org/10.1016/j.bbadis.2011.11.014 CrossRefPubMed

Kalyanaraman B, Darley-Usmar V, Davies KJA, Dennery PA, Forman HJ, Grisham MB, Mann GE, Moore K, Roberts LJ II, Ischiropoulos H (2012) Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radic Biol Med 52:1–6. https://doi.org/10.1016/j.freeradbiomed.2011.09.030 CrossRefPubMed

Kegel KB, Meloni AR, Yi Y, Kim YJ, Doyle E, Cuiffo BG, Sapp E, Wang Y, Qin ZH, Chen JD, Nevins JR, Aronin N, DiFiglia M (2002) Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem 277:7466–7476. https://doi.org/10.1074/jbc.M103946200 CrossRefPubMed

Kuhl DE, Phelps ME, Markham CH, Metter EJ, Riege WH, Winter J (1982) Cerebral metabolism and atrophy in huntington’s disease determined by18FDG and computed tomographic scan. Ann Neurol 12:425–434. https://doi.org/10.1002/ana.410120504 CrossRefPubMed

Li S-H, Li X-J, Zoghbi H et al (2004) Huntingtin–protein interactions and the pathogenesis of Huntington’s disease. Trends Genet 20:146–154. https://doi.org/10.1016/j.tig.2004.01.008 CrossRefPubMed

Manatt M, Chandra SB (2011) The effects of mitochondrial dysfunction in schizophrenia. J Med Genet Genomics 3:84–94

Marchina E, Misasi S, Bozzato A, Ferraboli S, Agosti C, Rozzini L, Borsani G, Barlati S, Padovani A (2014) Gene expression profile in fibroblasts of Huntington’s disease patients and controls. J Neurol Sci 337:42–46. https://doi.org/10.1016/j.jns.2013.11.014 CrossRefPubMed

Mason RP, Casu M, Butler N, Breda C, Campesan S, Clapp J, Green EW, Dhulkhed D, Kyriacou CP, Giorgini F (2013) Glutathione peroxidase activity is neuroprotective in models of Huntington’s disease. Nat Genet 45:1249–1254. https://doi.org/10.1038/ng.2732 CrossRefPubMedPubMedCentral

Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L, le Bouc Y, Gervais C, Carcelain G, Vassault A, Feingold J, Rabier D, Durr A (2007) Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One 2:e647. https://doi.org/10.1371/journal.pone.0000647 CrossRefPubMedPubMedCentral

Orr AL, Li S, Wang C-E, Li H, Wang J, Rong J, Xu X, Mastroberardino PG, Greenamyre JT, Li XJ (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci 28:2783–2792. https://doi.org/10.1523/JNEUROSCI.0106-08.2008 CrossRefPubMedPubMedCentral

Panov AV, Gutekunst C-A, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT (2002) Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci 5:731–736. https://doi.org/10.1038/nn884 CrossRefPubMed

Parker WD, Boyson SJ, Luder AS, Parks JK (1990) Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington’s disease. Neurology 40:1231–1234CrossRef

Petersen MH, Budtz-Jørgensen E, Sørensen SA, Nielsen JE, Hjermind LE, Vinther-Jensen T, Nielsen SMB, Nørremølle A (2014) Reduction in mitochondrial DNA copy number in peripheral leukocytes after onset of Huntington’s disease. Mitochondrion 17:14–21. https://doi.org/10.1016/j.mito.2014.05.001 CrossRefPubMed

Pierzynowska K, Gaffke L, Cyske Z, Puchalski M, Rintz E, Bartkowski M, Osiadły M, Pierzynowski M, Mantej J, Piotrowska E, Węgrzyn G (2018a) Autophagy stimulation as a promising approach in treatment of neurodegenerative diseases. Metab Brain Dis 33:989–1008. https://doi.org/10.1007/s11011-018-0214-6 CrossRefPubMedPubMedCentral

Pierzynowska K, Gaffke L, Hać A, Mantej J, Niedziałek N, Brokowska J, Węgrzyn G (2018b) Correction of Huntington’s disease phenotype by genistein-induced autophagy in the cellular model. NeuroMolecular Med 20:112–123. https://doi.org/10.1007/s12017-018-8482-1 CrossRefPubMedPubMedCentral

Powers WJ, Haas RH, Le T et al (2007) Normal platelet mitochondrial complex I activity in Huntington’s disease. Neurobiol Dis 27:99–101. https://doi.org/10.1016/j.nbd.2007.04.008 CrossRefPubMedPubMedCentral

Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JTJ, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, Karp NA, Hester S, Tkachev D, Mimmack ML, Yolken RH, Webster MJ, Torrey EF, Bahn S (2004) Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9:684–697. https://doi.org/10.1038/sj.mp.4001511 CrossRefPubMed

Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N (2012) The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord 27:1083–1091. https://doi.org/10.1002/mds.25075 CrossRefPubMed

Quintanilla RA, Johnson GVW (2009) Role of mitochondrial dysfunction in the pathogenesis of Huntington’s disease. Brain Res Bull 80:242–247. https://doi.org/10.1016/j.brainresbull.2009.07.010 CrossRefPubMedPubMedCentral

Rajasekaran A, Venkatasubramanian G, Berk M, Debnath M (2015) Mitochondrial dysfunction in schizophrenia: pathways, mechanisms and implications. Neurosci Biobehav Rev 48:10–21. https://doi.org/10.1016/J.NEUBIOREV.2014.11.005 CrossRefPubMed

Reddy PH, Mao P, Manczak M (2009) Mitochondrial structural and functional dynamics in Huntington’s disease. Brain Res Rev 61:33–48. https://doi.org/10.1016/j.brainresrev.2009.04.001 CrossRefPubMedPubMedCentral

Ribeiro M, Rosenstock TR, Cunha-Oliveira T, Ferreira IL, Oliveira CR, Rego AC (2012) Glutathione redox cycle dysregulation in Huntington’s disease knock-in striatal cells. Free Radic Biol Med 53:1857–1867. https://doi.org/10.1016/J.FREERADBIOMED.2012.09.004 CrossRefPubMed

Robinson KM, Janes MS, Beckman JS (2008) The selective detection of mitochondrial superoxide by live cell imaging. Nat Protoc 3:941–947. https://doi.org/10.1038/nprot.2008.56 CrossRef

Roos RA (2010) Huntington’s disease: a clinical review. Orphanet J Rare Dis 5:40. https://doi.org/10.1186/1750-1172-5-40 CrossRefPubMedPubMedCentral

Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A (2009) Huntington’s disease: the current state of research with peripheral tissues. Exp Neurol 219:385–397. https://doi.org/10.1016/j.expneurol.2009.05.012 CrossRefPubMed

Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson MA, Gusella JF, Laramie JM, Myers RH, Lesort M, MacDonald ME (2005) HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 14:2871–2880. https://doi.org/10.1093/hmg/ddi319 CrossRefPubMed

Sharp AH, Loev SJ, Schilling G, Li SH, Li XJ, Bao J, Wagster MV, Kotzuk JA, Steiner JP, Lo A, Hedreen J, Sisodia S, Snyder SH, Dawson TM, Ryugo DK, Ross CA (1995) Widespread expression of Huntington’s disease gene (IT15) protein product. Neuron 14:1065–1074CrossRef

Snyder SH, Sawa A, Wiegand GW et al (1999) Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 5:1194–1198. https://doi.org/10.1038/13518 CrossRefPubMed

Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC, TRACK-HD investigators (2009) Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8:791–801. https://doi.org/10.1016/S1474-4422(09)70170-X CrossRefPubMedPubMedCentral

The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983CrossRef

Turner C, Cooper JM, Schapira AHV (2007) Clinical correlates of mitochondrial function in Huntington’s disease muscle. Mov Disord 22:1715–1721. https://doi.org/10.1002/mds.21540 CrossRefPubMed

Valencia A, Sapp E, Kimm JS, McClory H, Reeves PB, Alexander J, Ansong KA, Masso N, Frosch MP, Kegel KB, Li X, DiFiglia M (2013) Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington’s disease. Hum Mol Genet 22:1112–1131. https://doi.org/10.1093/hmg/dds516 CrossRefPubMed

Wang H, Lim PJ, Karbowski M, Monteiro MJ (2009) Effects of overexpression of Huntingtin proteins on mitochondrial integrity. Hum Mol Genet 18:737–752. https://doi.org/10.1093/hmg/ddn404 CrossRefPubMed

Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X (2014) Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochim Biophys Acta 1842:1240–1247. https://doi.org/10.1016/j.bbadis.2013.10.015 CrossRefPubMed

Zielonka J, Kalyanaraman B (2010) Hydroethidine- and MitoSOX-derived red fluorescence is not a reliable indicator of intracellular superoxide formation: another inconvenient truth. Free Radic Biol Med 48:983–1001. https://doi.org/10.1016/j.freeradbiomed.2010.01.028 CrossRefPubMedPubMedCentral

Zielonka J, Vasquez-Vivar J, Kalyanaraman B (2008) Detection of 2-hydroxyethidium in cellular systems: a unique marker product of superoxide and hydroethidine. Nat Protoc 3:8–21. https://doi.org/10.1038/nprot.2007.473 CrossRefPubMed

Zielonka D, Piotrowska I, Marcinkowski JT, Mielcarek M (2014) Skeletal muscle pathology in Huntington’s disease. 5:380. https://doi.org/10.3389/fphys.2014.00380

Title: Mitochondrial alterations accompanied by oxidative stress conditions in skin fibroblasts of Huntington’s disease patients
Authors: Paulina Jędrak
Paweł Mozolewski
Grzegorz Węgrzyn
Mariusz R. Więckowski
Publication date: 01-12-2018
Publisher: Springer US
Published in: Metabolic Brain Disease / Issue 6/2018
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-018-0308-1

At a glance: The STEP trials

Springer Medicine

Mitochondrial alterations accompanied by oxidative stress conditions in skin fibroblasts of Huntington’s disease patients

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Therapeutic effects of probiotics on neurotoxicity induced by clindamycin and propionic acid in juvenile hamsters

MEDNIK syndrome with a frame shift causing mutation in AP1S1 gene and literature review of the clinical features

Oxymatrine attenuates brain hypoxic-ischemic injury from apoptosis and oxidative stress: role of p-Akt/GSK3β/HO-1/Nrf-2 signaling pathway

Leptin stimulates the release of pro-inflammatory cytokines in hypothalamic astrocyte cultures from adult and aged rats

Standardized Citrus unshiu peel extract ameliorates dexamethasone-induced neurotoxicity and depressive-like behaviors in mice

Ameliorative effects of hydrogen sulfide (NaHS) on chronic kidney disease-induced brain dysfunction in rats: implication on role of nitric oxide (NO) signaling